Single-agent monoclonal antibody trials.
| Study . | Monoclonal Antibody . | Prior Rx . | No. Pts. Evaluable . | % CR . | % OR . | Median TTP (mo) . |
|---|---|---|---|---|---|---|
| Abbreviations: Rx, treatment; CR, complete remission; OR, overall response; IV, intravenous; SQ, subcutaneous; TIW, thrice weekly; NA, not available; NR, not reached; TTP, time-to-progression for responders | ||||||
| * Fludarabine refractory | ||||||
| ** Three patients received 250 mg/m2 TIW for 4 weeks | ||||||
| *** Updated as presented | ||||||
| Alemtuzumab | ||||||
| Keating21 | 30 mg IV TIW × 12 wk | Yes* | 93 | 2 | 33 | 9 |
| Osterborg22 | 30 mg IV TIW × 12 wk | Yes | 29 | 4 | 42 | 12 |
| Rai23 | 30 mg IV TIW × 16 wk | Yes | 24 | 0 | 33 | 19.6 |
| Ferrajoli24 | 30 mg IV TIW × 12 wk | Yes | 42 | 5 | 31 | NA |
| Moreton5 | 30 mg IV TIW × 16 wk | Yes | 91 | 35 | 54 | NA |
| Stilgenbauer25 | 30 mg SQ TIW × 12 wk | Yes* | 44 | 4 | 36 | 10 |
| Lundin26 | 30 mg SQ TIW × 18 wk | No | 41 | 19 | 87 | NR |
| Rituximab | ||||||
| McLaughlin30 | 375 mg/m2 IV weekly × 4 | Yes | 30 | 0 | 13 | NA |
| Huhn32 | 375 mg/m2 IV weekly × 4 | Yes | 28 | 0 | 25 | 5 |
| O’Brien33 | 500–825 mg/m2 IV weekly × 4 | Yes | 24 | 0 | 21 | |
| 1000–1500 mg/m2 IV weekly × 4 | Yes | 7 | 0 | 43 | 8 | |
| 2250 mg/m2 IV weekly × 4 | Yes | 8 | 0 | 75 | ||
| Byrd34 | 375 mg/m2 IV TIW × 4 wk** | No/Yes | 29 | 4 | 52 | 11 |
| Hainsworth59 | 375 mg/m2 IV weekly × 4 then q 6 mo for 2 yr | No | 43 | 9 | 58 | 19 |
| Study . | Monoclonal Antibody . | Prior Rx . | No. Pts. Evaluable . | % CR . | % OR . | Median TTP (mo) . |
|---|---|---|---|---|---|---|
| Abbreviations: Rx, treatment; CR, complete remission; OR, overall response; IV, intravenous; SQ, subcutaneous; TIW, thrice weekly; NA, not available; NR, not reached; TTP, time-to-progression for responders | ||||||
| * Fludarabine refractory | ||||||
| ** Three patients received 250 mg/m2 TIW for 4 weeks | ||||||
| *** Updated as presented | ||||||
| Alemtuzumab | ||||||
| Keating21 | 30 mg IV TIW × 12 wk | Yes* | 93 | 2 | 33 | 9 |
| Osterborg22 | 30 mg IV TIW × 12 wk | Yes | 29 | 4 | 42 | 12 |
| Rai23 | 30 mg IV TIW × 16 wk | Yes | 24 | 0 | 33 | 19.6 |
| Ferrajoli24 | 30 mg IV TIW × 12 wk | Yes | 42 | 5 | 31 | NA |
| Moreton5 | 30 mg IV TIW × 16 wk | Yes | 91 | 35 | 54 | NA |
| Stilgenbauer25 | 30 mg SQ TIW × 12 wk | Yes* | 44 | 4 | 36 | 10 |
| Lundin26 | 30 mg SQ TIW × 18 wk | No | 41 | 19 | 87 | NR |
| Rituximab | ||||||
| McLaughlin30 | 375 mg/m2 IV weekly × 4 | Yes | 30 | 0 | 13 | NA |
| Huhn32 | 375 mg/m2 IV weekly × 4 | Yes | 28 | 0 | 25 | 5 |
| O’Brien33 | 500–825 mg/m2 IV weekly × 4 | Yes | 24 | 0 | 21 | |
| 1000–1500 mg/m2 IV weekly × 4 | Yes | 7 | 0 | 43 | 8 | |
| 2250 mg/m2 IV weekly × 4 | Yes | 8 | 0 | 75 | ||
| Byrd34 | 375 mg/m2 IV TIW × 4 wk** | No/Yes | 29 | 4 | 52 | 11 |
| Hainsworth59 | 375 mg/m2 IV weekly × 4 then q 6 mo for 2 yr | No | 43 | 9 | 58 | 19 |